Peter Fecci

Peter Edward Fecci is a prominent American neurosurgeon and researcher, currently serving as the Deputy Director at the Preston Robert Tisch Brain Tumor Center at Duke University. He holds multiple academic titles, including Associate Professor of Neurosurgery, Pathology, and Immunology, as well as positions in Biomedical Engineering and Integrative Immunobiology at the Duke University School of Medicine.

Education and Training

• Bachelor of Science in Neurobiology and Behavior from Cornell University (1999).
• M.D. and Ph.D. from Duke University (2007), with his doctoral research focusing on regulatory T cells in glioblastoma.
• Completed a Neurosurgical residency at Massachusetts General Hospital (2008-2013).

Professional Experience

• Deputy Director, Preston Robert Tisch Brain Tumor Center (April 2018 - Present).
• Director, Brain Tumor Immunotherapy Program at Duke University Medical Center (August 2014 - Present).
• Director, Duke Center for Brain and Spine Metastasis (March 2017 - Present).
• Previous roles include Residency Program Director at Duke and Co-Director of the North Neurosurgical Service at Massachusetts General Hospital.

Research Focus

Fecci's research primarily revolves around:

• Brain tumor immunology and immunotherapy, particularly targeting T cell dysfunction in glioblastoma.
• Development of clinical trials for both primary and metastatic brain tumors.
• Exploration of novel technologies such as laser-induced interstitial thermal therapy (LITT) and nanotechnologies.

He has authored over 60 scientific articles and holds two active patents related to his research. His work aims to enhance immune-based therapies for brain tumors, striving for a multidisciplinary approach that integrates various specialties within neuro-oncology.

Recognitions

Fecci has received numerous accolades, including:

• The Sontag Distinguished Scientist Award (2015).
• The Prince Mahidol Youth Mentor Award (2016).
• The Duke Health Scholars Award (2016).

His contributions to neurosurgery and cancer research have established him as a leader in the field, particularly in advancing therapeutic strategies for brain tumors.